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A B S T R A C T
Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent inherited kidney disease.
Transepithelial fluid secretion is one of the key factors of cystogenesis in ADPKD. Multiple studies have sug-
gested that fluid secretion across ADPKD cyst-lining cells is driven by the secretion of chloride, essentially
mediated by the CFTR channel and stimulated by increased intracellular levels of 3′,5′-cyclic adenosine
monophosphate. This review focuses on the pathophysiology of fluid secretion in ADPKD based on the pio-
neering studies of Jared Grantham and colleagues, and on the follow-up investigations from the molecular level
to the potential applications in ADPKD patients. Altogether, the studies of fluid and chloride transport in ADPKD
paved the way for innovative therapeutic targets to prevent cyst volume expansion and thus, kidney disease
progression.
CLS-D-20-00256.R1.
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Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is the most
common inherited disease of the kidney, accounting for up to 10% of
patients requiring dialysis or transplantation [1]. ADPKD is genetically
heterogeneous, with mutations in PKD1 and PKD2 accounting for
~80% and ~ 15% of the cases, respectively [2]. The PKD1 and PKD2
genes encode the membrane proteins, polycystin-1 and polycystin-2
respectively, which are expressed in distinct domains and play multiple
roles in kidney tubular cells homeostasis [3–7]. It is generally accepted
that the polycystins interact and are expressed in the primary cilia;
mutations in PKD1/PKD2 impact multiple ciliary-dependent signaling
pathways and alter intracellular Ca2+ homeostasis [3,5,6]. Mutations
of at least 5 genes (i.e., GANAB, PRKCSH, ALG8, SEC61B, and SEC63),
which encode proteins in the endoplasmic reticulum involved in ma-
turation and proper surface localization of integral membrane proteins
including polycystin-1 and polycystin-2, have been shown to cause mild
forms of ADPKD with variable cystic liver disease severity [2,8–10].
The kidney cysts observed in patients with ADPKD derive from 1%
to 3% of the nephrons. They potentially involve all tubular segments,
although an important fraction of the cysts derives from the collecting
ducts [11,12]. The prospective follow-up of ADPKD patients with yearly
magnetic resonance imaging (MRI) examinations in the CRISP cohort
has established that cysts increase at a stable rate of ~5% per year [13]
and that total kidney volume (TKV) is the strongest predictor of renal
function decline in ADPKD [14]. The determination of TKV is globally
considered as a useful marker to assess disease progression in ADPKD
patients [15]. In terms of clinical trials, the official position of US and
European regulators is that TKV is best used as a prognostic biomarker
and is a reasonably likely surrogate end point, and basis for accelerated
approval [16].
The development of kidney cysts in ADPKD requires a set of com-
plex phenotype changes in the tubular cells. These changes include
abnormal proliferation, loss of differentiation, changes in polarity, al-
tered migration, abnormalities in the extracellular matrix, and meta-
bolic disturbances [17–19]. In 1987, J. Grantham and colleagues re-
ported on a detailed characterization of cysts from 10 sets of kidneys
obtained from adult patients with ADPKD. They remarkably observed
that the vast majority of cysts had no tubule connections, indicating
that the cystic fluid does not originate from the glomerular filtrate but
rather from transepithelial fluid secretion [20]. As pointed by Gran-
tham in his 2003 Lillian Jean Kaplan Prize lecture, “respectable mam-
malian renal tubules are supposed to reabsorb glomerular filtrate […] and I
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was going to tell that our sacred nephron was converted into the equivalent
of a tear duct, or a sweat duct…” [21]. Yet, in original experiments
conducted in the early 1970's, Grantham demonstrated that isolated
proximal tubules perfused in vitro change from absorbing to secreting
fluid when a solute (e.g. para-aminohippurate, PAH) is added to the
external bath and secreted into the lumen by the tubular cells [22]. The
existence of such a fluid secretion, regulated by 3′,5′-cyclic adenosine
monophosphate (cAMP) is now considered as a key driver for the for-
mation and expansion of kidney cysts in ADPKD [1,21,23–25]. Here, we
will briefly review the pathophysiology of fluid secretion in ADPKD
based on the classic studies performed by Grantham and colleagues,
and the translational insights that led to novel therapeutic pathways in
ADPKD.
Electrophysiological properties of kidney cysts
A first step in understanding cyst formation in ADPKD came from
the analysis of cyst fluid composition. Assuming that kidney cysts arise
from any tubular segment, cyst fluid composition should reflect its
tubular origin. Gardner classified ADPKD cysts into two categories ac-
cording to the Na+ concentration above or below 100 mmol/l [26].
Huseman and Grantham suggested that cysts with a low [Na+] (“gra-
dient cysts”) derive from tight distal nephron segments, whereas cysts
exhibiting a high [Na+] (“no gradient cysts”) most probably derive
from leaky proximal tubule segments [27]. By measuring the electrical
parameters of cyst-lining epithelia mounted in Ussing chambers, Per-
rone showed that “gradient cysts” exhibit a transepithelial resistance
similar to tight epithelia, with a transepithelial potential difference
(−5 mV, lumen negative) inhibitable by apical amiloride [28]. These
observations indicate that the electrical current reflects Na+ re-
absorption. Note that a net secretory flux of 22Na across monolayers of
cystic cells was also reported, potentially driven by mispolarized Na+-
K+-ATPase or, alternatively, by a primary secretion of Cl− anions [29].
Transepithelial chloride secretion in ADPKD
The existence of abnormal fluid secretion through the epithelial
cells lining the ADPKD cysts came from the observation that a kidney
cyst rapidly fills again after drainage [30]. The classical studies of
Grantham and colleagues deciphered the in vitro and ex vivo me-
chanisms involved in ADPKD-associated fluid secretion [23,31]. The
transport of Cl− was established as the driving force of fluid secretion in
monolayers of ADPKD cyst cells [23,32,33]. Fluid secretion could be
stimulated by adenylyl cyclase agonists, as well as by the phospho-
diesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX) or by 8-Br-
cAMP, a form of cAMP insensitive to hydrolysis by phosphodiesterase.
Note that forskolin-induced fluid secretion was associated with an in-
creased electronegativity in cyst lumen. Conversely, the addition of
bumetanide in the basolateral medium or the Cl− channel inhibitor
diphenylamine-2-carboxylate (DPC) on the apical side inhibited fluid
secretion in cystic cells [32,33]. The latter observations indicate that a
NKCC cotransporter (SLC12A1 or SLC12A2) may play a role in Cl−
entrance in cyst-lining cells.
Expression of CFTR and other chloride transporters in ADPKD
The analogy between the properties of the ADPKD cystic epithelium
and those of other secretory epithelia suggested that the cystic fibrosis
transmembrane regulator (CFTR) channel could be the molecular
counterpart of the cAMP-stimulated Cl− secretion in ADPKD cysts
(Fig. 1). The expression of CFTR was first evidenced in primary cultures
of ADPKD cells and ADPKD kidney extracts, with an immunostaining
pattern compatible with localization to the apical membrane of cyst-
lining cells [34]. Selective Cl− currents were recorded in cultured
ADPKD cyst cells. These currents were stimulated by forskolin or a
permeant analogue of cAMP, but were totally inhibited by the CFTR
blocker DPC [34]. A significant heterogeneity in CFTR expression was
reported in cyst-lining epithelia, possibly caused by cell dedifferentia-
tion [34–36]. Thus, a subset of tubular cells with functional CFTR may
be sufficient to drive fluid secretion into the cyst or, alternatively, other
types of Cl− transporters might be implicated in fluid secretion [37].
CFTR was also detected at the apical cell membrane of kidney cyst-
lining cells in a Pkd1 KO mouse model, consistent with its role in cAMP-
dependent fluid secretion [38].
Considering the heterogeneous expression of CFTR in ADPKD cysts,
the possibility that alternative pathways participate in Cl− and fluid
secretion has been explored. In particular, Kunzelmann et al. discovered
that the calcium-activated Cl− secretion by anoctamin 1 (ANO1, also
named TMEM16A), activated through purinergic (P2Y2) receptors,
plays a role in epithelial fluid secretion and proliferation, using prin-
cipal cells from dog (MDCK) and mouse (M1) kidneys and an embryonic
kidney cyst model [39,40]. This pathway may be linked to local hy-
poxia, secondary to cyst growth, and stabilization of the hypoxia-in-
ducible transcription factor-1α (HIF-1α), which regulates cyst growth
in vitro via calcium-activated Cl− secretion [41]. The relevance of these
findings needs to be substantiated in vivo, as for instance ANO1 appears
to be cytoplasmic or even located on the basolateral membrane in
human ADPKD cyst-lining cells [42].
The nature of the Cl− transporters involved on the basolateral side
of the cells was investigated by Lebeau et al. [43]. They detected
NKCC1 in ADPKD cells and kidney extracts, with a basolateral re-
activity in about one-third of ADPKD cysts. Staining of serial sections
showed that cysts expressing NKCC1 were also positive for CFTR. The
fact that most CFTR-positive ADPKD cysts also expressed NKCC1 sug-
gested that transepithelial Cl− secretion in ADPKD involves molecular
mechanisms similar to secretory epithelia. This conclusion was sup-
ported by the demonstration of NKCC1 in the basolateral membranes of
advanced cystic lesions in the Pkd2WS25/− mouse model [44]. Lebeau
et al. also showed that the Cl−/HCO3
− anion exchanger type I (AE1),
which operates in the basolateral membrane of α-type intercalated cells
of the collecting ducts, is detected at the basolateral pole of CFTR-po-
sitive, NKCC1-negative ADPKD cysts. Accordingly, AE1 might be an
alternative basolateral pathway for Cl− conductance in a subpopulation
of cysts [43].
The sustained activity of NKCC1 in the basolateral membrane of cyst
epithelial cells requires basolateral recycling of K+ and Na+, as well as
the maintenance of a hyperpolarized membrane potential (Fig. 1). Al-
baqumi and colleagues demonstrated the role of the Ca2+-activated
potassium channel KCa3.1 in mediating the efflux of K+ and main-
taining a relatively negative intracellular membrane potential that
drives the apical Cl− secretion by CFTR in monolayers of kidney cells
derived from patients with ADPKD [45]. Both cAMP and PKA may
activate KCa3.1 channels, which appears relevant given the importance
of cAMP in the pathogenesis of ADPKD [24].
CFTR structure, function and localization in the kidney
The CFTR protein belongs to the superfamily of the integral mem-
brane ATP-binding cassette (ABC) transporters [46]. These mediators of
unidirectional organic solute transport include multidrug resistance
proteins, such as MDR and P-glycoprotein, and a number of prokaryotic
and eukaryotic small nutrient transporters [47]. CFTR is symmetrically
structured in 2 transmembrane domains (TMD1 and TMD2) and 2 nu-
cleotide binding domains (NBD1 and NBD2), separated by a large,
polar, regulatory (R) domain. Each membrane-spanning domain is
made of 6 α-helices, portions of which form the Cl− pore (Fig. 2). CFTR
is regulated by cAMP-dependent phosphorylation of the R domain via
the protein kinase A (PKA), followed by ATP-dependent gating events
initiated by ATP binding to the cytoplasmic nucleotide-binding do-
mains (NBD1 and NBD2) and resulting in transepithelial Cl− transport
[46,48]. CFTR channel gating is strictly coupled to phosphorylation and
ATP hydrolysis [49]. Following phsophorylation, the R domain is
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disengaged from its inhibitory position; the NBDs form a “head-to-tail”
dimer upon binding ATP; and the cytoplasmic pathway is cracked open.
Note that local movements of the transmembrane helices may also
participate to ion access to the pore even in the NBD-dimerized con-
formation [49].
The N- and C-termini of CFTR are both oriented to the intracellular
compartment. The C-terminus of CFTR harbors a type I PDZ domain-
binding motif, which interacts with several PDZ-domain proteins in-
cluding the Na+/H+ exchange regulatory factors (NHE-RF1 and NHE-
RF2) and the actin-binding protein ezrin [50]. The dynamic regulation
of CFTR binding to these scaffolds may participate to its dimeric or-
ganization into macromolecular functional units containing regulatory
partners and other channels. The insertion of CFTR channels in the
plasma membrane also involves a complex of proteins including the
PDZ-domain proteins NHERF1 and CAL, as well as the SNARE SYN6
and the Rho GTPase TC10 and several Rab GTPases [51,52]. There,
CFTR interacts functionally with other channels, including the out-
wardly rectifying Cl− channels (ORCC) and the Na+ channel ENaC, and
it participates in the exocytosis and formation of membrane macro-
molecular complexes [52]. Finally, CFTR does not only transport Cl−
but also ATP. The CFTR-mediated transport of ATP may be involved in
the control of EnaC and other channels [53].
CFTR is located in the apical membrane of numerous secretory
epithelia, including airways, sweat and pancreatic ducts, colonic crypts,
and male genital tract [48]. CFTR is expressed in the developing and
mature mammalian kidney [54–57]. By immunostaining, CFTR was
Fig. 1. Role of chloride transport and cAMP in
ADPKD cyst-lining cells.
A cyst-lining tubular cell (from the collecting duct),
with tight junctions delineating the apical and ba-
solateral poles, is depicted. The complex involving
polycystin-1 (PC1) and polycystin-2 (PC2) mediates
Ca2+ fluxes in response to stimuli sensed by the
primary cilium (apical pole). Disruption of the PC1-
PC2 complex is involved in the alteration of in-
tracellular Ca2+ levels. PC2 is also involved in the
regulation of Ca2+ stores from the endoplasmic re-
ticulum (ER). The transepithelial secretion of Cl− is
mediated by the basolateral Na+-K+-2Cl− co-
transporter NKCC1 and apical Cl− channels in-
cluding the protein kinase A (PKA)-stimulated CFTR.
The Cl−/HCO3
− anion exchanger type I (AE1) might
be an alternative basolateral pathway for Cl− in a
subpopulation of cysts. This transepithelial pathway
is stimulated by an increased concentration of cAMP,
probably reflecting reduced intracellular Ca2+ levels
(which stimulates of Ca2+-inhibitable adenylyl cy-
clase (AC) and/or inhibits the Ca2+-dependent
phosphodiesterase (PDE)) and stimulation of the
vasopressin V2 receptor (V2R) pathway. The activity
of NKCC1 requires the recycling of K+ via the ba-
solateral K+ channel KCa3.1 and that of Na+ via the
ubiquitous Na+-K+-ATPase (not shown). The increased cAMP levels stimulate PKA-mediated phosphorylation of various mediators, leading to disruption of flow
sensing and tubulogenesis; transepithelial fluid secretion driven by apical CFTR; increased expression of water channels (AQP2); and transcriptional regulation of
mediators involved in cell proliferation. The expression of CFTR and the net secretion of Cl− induces a transepithelial movement of Na+ (electric coupling) and water
(osmotic coupling). Note that CFTR is blocking the apical Na+ channel ENac, preventing Na+ reabsorption from the lumen. The main drugs targeting these transport
pathways are indicated in green boxes. For details, see text.
Other abbreviations: CREB, cAMP response element-binding protein; Gs, stimulatory G protein; Gi, inhibitory G protein; MAPK, mitogen-activated protein kinase;
mTOR, mammalian target of rapamycin; SST2, somatostatin receptor. (Adapted from Refs. 1, 18, 25).
Fig. 2. Representative 2-dimensional structure of
CFTR.
The CFTR protein contains two symmetric parts
made of 1 membrane-spanning domain (including 6
trans-membrane domains (TMD)) and 1 nucleotide-
binding domain (NBD), linked by an intracellular, R
(regulatory) domain. The phenylalanine most fre-
quently affected in Caucasian patients with cystic
fibrosis is located in NBD1 (Phe508). Ivacaftor (IVA,
a potentiator of CFTR) binds CFTR at the NDB1/2
interface and the coupling helix of intracellular loops
1 & 4 (L1/L4), whereas Lumacaftor (LUMA, a CFTR
corrector) binds NBD1.(Adapted from Refs. 65)
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found at the apical surface of both proximal and distal tubules of rat
kidney [54]. In mouse kidney, CFTR is mainly present in the apical area
of proximal tubule (PT) cells (pars recta, S3 segment), with a subcellular
distribution compatible with endosomes [58,59]. In the human kidney,
CFTR was detected in the PT, in addition to the thin limbs of Henle's
loop, distal tubules and collecting ducts [54–57]. Of note, a functional
truncated isoform (TNR-CFTR) made of the TMD1, NBD1 and R do-
mains has also been reported in rat and human kidney, with a specific
ontogeny pattern [55,56,60]. TNR-CFTR may function in intracellular
organelles and partially substitute CFTR functions in the kidney me-
dulla [61].
Besides its location in the plasma membrane, CFTR is present in
intracellular organelles along the endocytic and the secretory pathways.
There, CFTR may act as a pH regulator by importing Cl− in parallel to
H+ accumulation and thereby influencing vesicular acidification and,
potentially, activity of the endolysosomal and recycling compartments
[58,62–64].
Kidney phenotype in cystic fibrosis
Cystic fibrosis (CF; MIM #219700) is the most common lethal au-
tosomal recessive disease in Caucasians, with a prevalence of one in
2500 live births. CF is a multi-systemic disease that basically results
from the obstruction of exocrine glands by an excessive production of
mucus. The accumulation of thick, poorly hydrated mucus in the air-
ways causes an obstructive lung disease promoting chronic bacterial
infection and inflammation [65]. In 1989, Collins, Riordan and col-
leagues demonstrated that CF was caused by loss-of-function mutations
in the CFTR (also named, ABCC7) gene that encodes CFTR [66]. Over
2075 CF-associated mutations have been reported thus far in CFTR (CF
Genetic Analysis Consortium, http://www.genet.sickkids.on.ca/cftr/),
classified into 5 groups according to their structural or functional
consequences on Cl− conduction [65]. The in-frame deletion of 3 bases
encoding a phenylalanine residue at position 508 (ΔF508) represents
the most common mutation in CF population. The ΔF508 mutation
affects the correct processing and maturation of CFTR [67]. About 5 to
10% of CFTR mutations are due to premature truncation or non-sense
alleles. These are associated with the most severe CF phenotypes [68].
Most other CFTR mutations are unique to a particular family or to only
a handful of cases across the world.
The abundant expression of CFTR in the mammalian kidney sug-
gests that CFTR may play a role in (patho)-physiology [69]. Patients
with CF are prone to develop episodes of Bartter-like syndrome char-
acterized by dehydration with metabolic alkalosis [70,71]. A decreased
capacity to concentrate the urine has also been reported [72]. However,
some of these observations may reflect adaptations to excessive losses
of NaCl in sweat and feces. The incidence of kidney stones is apparently
increased in CF patients, and microscopic nephrocalcinosis has been
reported [73,74]. Modifications in lithogenic factors and impaired hy-
dration may also contribute to these observations.
CF patients show an enhanced renal clearance of several drugs in-
cluding aminoglycosides, pointing to a putative defect in receptor-
mediated endocytosis in PT cells [75,76]. By analogy to other in-
tracellular Cl− transporters such as the Cl−/H+ exchanger, ClC-5,
CFTR may play a role in membrane recycling and/or vesicular pH
regulation in kidney cells [57,64]. CFTR-null (Cftr−/−) mice showed a
significant increase in the urinary excretion of the low-molecular-
weight (LMW) protein Clara Cell protein (CC16, 16 kD) in comparison
to controls, reflecting a selective defect in receptor-mediated en-
docytosis [58]. The Cftr−/− mice also showed a decreased uptake of
radiolabeled 125I-β2-microglobulin and a lower renal uptake of ami-
noglycosides, compared to wild-type littermates, confirming the en-
docytic defect. The latter was explained by a loss of the apical receptor
cubilin in PT cells, due to its increased shedding in the urine, causing a
loss of cubilin ligands (e.g. transferrin, CC16) in the urine [58]. An
intermediate phenotype was observed in the ΔF508 mice. Taken
together, these data suggest that the lack of a functional CFTR in kidney
PT cells significantly perturbs receptor-mediated endocytosis, namely
via an accelerated shedding of cubilin from the brush border into the
urine. Accordingly, a mild but significant albuminuria and LMW pro-
teinuria was reported in a cohort of CF patients, all harboring at least
one ΔF508 mutation [58]. These findings may impact on the long-term
renal function, since LMW proteinuria can trigger tubule-interstitial
injury and chronic kidney disease. Moreover, the increased urinary loss
of the cubilin-ligand, transferrin, could participate in the iron defi-
ciency and lower circulating transferrin levels that are commonly re-
ported in CF patients [77].
CFTR may also play a more general role in kidney damage. In a
model of unilateral ureteral obstruction (UUO)-induced kidney fibrosis,
ΔF508 mice exhibited significantly higher β-catenin activity with ag-
gregated renal fibrogenesis. This could be rescued by overexpression of
CFTR, suggesting a potential therapeutic target against fibrosis via
CFTR-regulated Wnt/β-catenin signaling [78].
Role of CFTR in ADPKD
The role of CFTR in mediating Cl− and fluid secretion in ADPKD
was substantiated in vitro by the fact that forskolin-stimulated fluid
secretion was dramatically reduced after incubation of monolayers of
ADPKD cells with an antisense oligonucleotide against CFTR [35].
Studies using primary cultures of ADPKD vs. control epithelial cells
confirmed the role of cAMP in stimulating cell proliferation as well as
fluid secretion and cyst enlargement [79]. The use of CFTR blockers
(e.g. glibenclamide, NPPB, genistein) reduced cyst growth and cAMP-
stimulated Cl− currents in MDCK cyst in collagen gel [80]. Further-
more, the thiazolidinone inhibitor CFTRinh-172, which stabilizes the
channel in the closed state, inhibits cyst growth in MDCK cells and in
metanephric kidney organ culture [81,82]. Two additional CFTR in-
hibitors (i.e. the tetrazolo-CFTRinh-172 and the phenyl-derived glycine
hydrazide Ph-GlyH-101) suppressed cyst growth in MDCK cells without
affecting cell proliferation; inhibited cyst number and growth in a
cAMP-stimulated embryonic kidney cyst model; and, remarkably,
slowed kidney enlargement and cyst growth and preserved renal
function in a neonatal, kidney-specific Pkd1 knock-out model (Pkd1flox/
−:Ksp-Cre mice) [83].
Jansson et al. observed that physiological concentrations of ouabain
in the presence of forskolin or 8-bromo-cAMP significantly enhanced
fluid secretion and cyst growth of cultured human ADPKD cell mono-
layers and microcysts in collagen matrix. Ouabain was also promoting
cAMP-dependent cyst enlargement in metanephric organ cultures from
Pkd1 compared to wild-type mouse kidneys [84]. In subsequent studies,
these investigators demonstrated that apical CFTR activation mediates
the cAMP-induced fluid secretion and cyst growth promoted by ouabain
[85]. In M1 cells derived from mouse cortical collecting duct, treatment
with vasopressin (AVP) increased the levels of CFTR protein and mRNA,
which, in turn, increased CFTR-mediated short-circuit currents [86].
From these collective data, the current model of cyst formation in
ADPKD starts with the loss of function of the polycystin-1/polycystin-2
complex. When the residual activity of that complex is under a critical
threshold, a cascade of changes in the cellular phenotype is triggered.
These changes include loss of tubular cell differentiation, abnormal
proliferation and changes in the surrounding tissue. Increased levels of
cAMP, resulting from the activation of G-protein-coupled receptors in-
cluding the vasopressin V2 receptor, activate protein kinase A (PKA)-
dependent pathways and cAMP-sensitive ion channels, essentially
CFTR, that mediate cyst fluid accumulation (Fig. 1). Importantly, cAMP
is also stimulating proliferation of cyst-lining cells, via PKA, B-Raf and
the MEK-1 and ERK kinase [1,21]. The release of ATP (and adenosine)
in the lumen may also stimulate the secretion of Cl−, and thus cyst
growth, through other types of Cl− channels [87,88].
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Potential therapeutic role of CFTR inhibitors in ADPKD
The data summarized above substantiate a role for CFTR in med-
iating cyst fluid accumulation in ADPKD. The potential of targeting
CFTR to decrease fluid secretion, and thus slow kidney cyst enlarge-
ment (e.g. TKV) in ADPKD has long been proposed [34,35,80,89,90].
Genetic evidence apparently concurred, since a milder cystic phenotype
was reported in 3 ADPKD patients with concomitant CF, as compared to
siblings with ADPKD alone [91,92]. Such protective effect was not
confirmed in a detailed analysis of kidney volume and function in 4
ADPKD individuals harboring the ΔF508 mutation at the homozygous
or heterozygous state – compared to ADPKD controls. The lack of
protective effect in these patients could be due to the persistent ex-
pression of mutant CFTR with an apical pattern in a large fraction of
ADPKD cysts [93]. To the best of our knowledge, the effect of a genetic
deletion of CFTR in an orthologous mouse model of ADPKD has not
been reported thus far.
As pointed by Verkman and colleagues, the use of CFTR inhibitors in
ADPKD would require a low toxicity profile, due to the nature of disease
and presumed long duration of treatment, a good penetration in the
cystic kidney, and a minimal accumulation in organs with active CFTR
(e.g. lungs, pancreas) [90]. Yang et al. screened small-molecule in-
hibitors of the thiazolidinone and glycine hydrazide classes in the
MDCK cell model [83]. They identified two lead compounds (tetrazolo-
CFTR(inh)-172 and Ph-GlyH-101) which blocked cyst growth without
affecting cell proliferation. These compounds also inhibited cystogen-
esis in an embryonic kidney cyst model. Subcutaneous administration
of these two compounds to neonatal, Pkd1 knockout mice for 7 days
slowed kidney enlargement and cyst expansion and preserved renal
function compared to vehicle-treated mice, at low micromolar EC50
range [83].
The class of (benzo)pyrimido-pyrrolo-quinoxalinedione (PPQ) in-
ihibitors of CFTR was also shown to inhibit cyst growth in an embryonic
kidney culture model of PKD, with a particular compound (BPO-27)
showing favorable pharmacokinetics and high efficacy (full inhibition
of CFTR with IC50 of ~8 nM) [94].
More recently, it was shown that steviol, the major metabolite of the
noncaloric sweetener stevioside, was able to inhibit cAMP-activated
chloride secretion by targeting CFTR and inhibit MDCK cyst growth, in
part by promoting CFTR degradation by the proteasome [95]. Early
postnatal administration of steviol in an orthologous mouse model of
human ADPKD (Pkd1flox/flox:Pkhd1-Cre) for 14 days markedly decreased
kidney weight and cystic index and blood urea nitrogen levels values,
compared to vehicle administration. Steviol also reduced cell pro-
liferation and CFTR expression (and mTOR/S6K) in kidney cyst-lining
epithelial cells. However, these results were only observed with i.p.
administration of high doses of steviol (200 mg/kg BW) [96]. The
proton pump inhibitor Lansoprazole has also been recently proposed to
reduce kidney cysts in vitro (MDCK cells) and in vivo (PCK rat), via
activation of the liver X receptor and subsequent down-regulation of
CFTR, with an additional anti-proliferative effect [97].
The VX-809 corrector of CFTR (Lumacaftor), which restores the
folding and trafficking of ΔF508-CFTR to the plasma membrane and
may also interact directly with the CFTR protein Fig. 2, was shown to
reduce cyst growth and to improve kidney function in a kidney-specific
Pkd1 mouse model and in proximal tubule-derived, cultured Pkd1
knockout cells. VX-809 was shown to reduce proliferation and to de-
crease both basal and forskolin-stimulated cAMP levels, while reducing
the thapsigargin-induced release of Ca2+ from the ER and increasing
the level of CFTR expression in the cells [98]. This result, which is
counterintuitive when considering the role of CFTR in mediating fluid
secretion and cyst growth, is probably due to an effect of the CFTR
corrector on cAMP levels, potentially mediated by a specific reduction
of adenylyl cyclase isoform 3 (AC3), and/or decreasing the Hsp90 le-
vels. Subsequent studies confirmed that VX-809 treatment of Pkd1-null
mouse kidneys changed the cyst phenotype from fluid secretion
towards fluid reabsorption, which could be due to increased expression
of the Na+-H+ exchanger NHE3 (proximal cysts) and Na+ channel
ENaC (collecting duct-derived cysts) [38]. The fact that the in vivo
effects of VX-809 were observed at doses lower than the doses used for
CF pediatric patients and the safety profile of the drug sustain the po-
tential interest of this CFTR corrector in ADPKD. An exploratory, ran-
domized, double-bling, placebo-controlled multicenter study evaluating
the efficacy, safety, tolerability and pharmacokinetics of the orally
administered CFTR corrector GLPG2737 in patients with ADPKD has
been initiated recently (Galapagos; EudraCT2019–003521-21).
On the basolateral side of the cyst cells, targeting NKCC1 with loop
diuretics could theoretically be envisaged, but the efficacy and safety of
such an approach remains very uncertain. In fact, a small-scale, non-
randomized study showed that hypertensive ADPKD patients treated
with diuretics had a faster loss of renal function compared to those
treated with ACE inhibitors, despite similar blood pressure control [99].
The clotrimazole analogue TRAM-34, which specifically inhibits the
Ca2+-activated K+ channel KCa3.1, inhibited forskolin-stimumated
Cl− secretion across the monolayers (without affecting CFTR or other
apical Cl− channels), and inhibited cyst formation and enlargement in
collagen matrix. It must be noted that such des-imidazolyl trityl deri-
vatives are already used in phase 3 clinical trials to block KCa3.1 in
sickle cell disease without side-effects, opening perspectives for further
testing in the ADPKD context [45,100].
Role of cAMP and vasopressin in ADPKD
Increased concentrations of cAMP play a central role in the pro-
gression of renal cystic disease in ADPKD (Fig. 1). Stimulation of the
V2R by the antidiuretic hormone arginine vasopressin (AVP) is the
major source of cAMP production in the collecting ducts [101]. Hap-
loinsufficiency in polycystin-1 in Pkd1+/− mice is associated with ex-
cessive AVP signaling, causing increased phosphorylation and recruit-
ment of aquaporin-2 water channels and inappropriate antidiuresis
[102]. The decreased intracellular Ca2+ concentration secondary to
PKD1/2 mutations may downregulate the Ca2+-dependent phospho-
diesterase PDE1 and stimulate the Ca2+ inhibitable adenylyl cyclase 6
(AC6), causing an increase in cAMP levels. In turn, increased cAMP
stimulates proliferation and growth of ADPKD cells and drives transe-
pithelial chloride and fluid secretion, through activation of protein ki-
nase A (PKA) and pathways including the mitogen-activated protein
kinase (MAPK) kinase MEK and the extracellular signal-regulated ki-
nase ERK, mTOR and Wnt-β-catenin, STAT3 and possibly PAX2 sig-
naling (25).
The crucial involvement of the V2R pathway in ADPKD was de-
monstrated by the significant effect of V2R antagonists including tol-
vaptan on kidney cyst development in various rodent models of PKD
(1,18). Suppression of endogenous AVP secretion by high water intake
was shown to attenuate the progression of kidney cysts in the PCK rat
[103]. Furthermore, kidney cyst development was inhibited in PCK rats
crossed to Brattleboro rats carrying a spontaneous mutation that ren-
ders them deficient in AVP, whereas administration of the V2R agonist
1-deamino-8-d-arginine vasopressin rescued the kidney cyst phenotype
[104]. These compelling results motivated the initiation of randomized
clinical trials, which demonstrated that the use of tolvaptan effectively
slows the rate of decline in kidney function in patients with ADPKD and
at risk of rapid disease progression [105,106].
Epilogue: When discussing the forces behind his quest to understand
ADPKD, Jared Grantham first mentioned his best childhood friend and his
family, affected by the disease. This emotional drive, coupled to a formidable
investigative mind, experimental rigor, willingness to translate research in-
sights into clinical gain, and exceptional managerial and personal qualities
led to discoveries that transformed the care of ADPKD. The visionary quest
of Jared Grantham was rooted in his interest for epithelial transport, paving
the way for the first treatment able to slow the progression of ADPKD:
blocking the vasopressin-cAMP pathway, thus interfering with cyst fluid
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